Corbilta 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IG/1580 
A.7 - Administrative change - Deletion of 
12/01/2023 
manufacturing sites 
Annex II and 
PL 
PSUSA/547/2
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
02110 
carbidopa / entacapone / levodopa 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
WS/2202/G 
This was an application for a group of variations 
31/03/2022 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.z - Quality change - Active substance - Other 
variation 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IG/1495 
B.III.1.a.2 - Submission of a new/updated or 
14/03/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
WS/2175 
This was an application for a variation following a 
27/01/2022 
16/12/2022 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
Page 2/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS/2105/G 
This was an application for a group of variations 
25/11/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
WS/2124/G 
This was an application for a group of variations 
16/09/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
Page 3/11 
 
 
 
 
 
 
 
 
 
 
 
 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IG/1408/G 
This was an application for a group of variations. 
17/06/2021 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IG/1303 
B.II.b.2.c.1 - Change to importer, batch release 
25/11/2020 
26/11/2021 
SmPC, Annex 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II, Labelling 
and PL 
N/0021 
Minor change in labelling or package leaflet not 
28/04/2020 
26/11/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
WS/1735/G 
This was an application for a group of variations 
12/03/2020 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
Page 4/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.d.1.b.3 - Stability of AS - Change in the storage 
conditions - Change in storage conditions of the AS 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
WS/1667/G 
This was an application for a group of variations 
05/12/2019 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
PSUSA/547/2
Periodic Safety Update EU Single assessment - 
29/05/2019 
25/07/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01810 
carbidopa / entacapone / levodopa 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/547/201810. 
Page 5/11 
 
 
 
 
 
 
 
 
 
 
 
 
IG/1060 
A.7 - Administrative change - Deletion of 
28/02/2019 
n/a 
manufacturing sites 
IG/0965/G 
This was an application for a group of variations. 
23/10/2018 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
R/0015 
Renewal of the marketing authorisation. 
26/04/2018 
06/07/2018 
SmPC 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Corbilta in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
WS/1327 
This was an application for a variation following a 
08/02/2018 
06/07/2018 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
IG/0867 
B.II.b.3.a - Change in the manufacturing process of 
20/11/2017 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
Page 6/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/0858/G 
This was an application for a group of variations. 
30/10/2017 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IG/0807 
A.5.b - Administrative change - Change in the name 
10/08/2017 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
II/0010 
C.I.13 - Other variations not specifically covered 
23/03/2017 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
II/0009 
C.I.13 - Other variations not specifically covered 
23/03/2017 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
Page 7/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/547/2
Periodic Safety Update EU Single assessment - 
13/05/2016 
n/a 
PRAC Recommendation - maintenance 
01510 
carbidopa / entacapone / levodopa 
IG/0631/G 
This was an application for a group of variations. 
04/12/2015 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0006 
Minor change in labelling or package leaflet not 
03/06/2015 
16/10/2015 
PL 
Page 8/11 
 
 
 
 
 
 
 
 
 
 
 
 
connected with the SPC (Art. 61.3 Notification) 
WS/0665 
This was an application for a variation following a 
22/01/2015 
16/10/2015 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
To update the Product Information as follows: 
- to include ADR statement 
- to update the PI to QRD template version 9 
- to include an explanation to the PL of the pictogram 
which is currently only displayed on the carton (all 
products except Comtan) 
- to correct the local contact information for Malta in 
Stalevo PL 
- to correct the local contact information for Latvia in 
all PLs except for Comtan and Entacapone Orion 
- to correct the local contact information for 
Germany in Comtess and 
Levodopa/Carbidopa/Entacapone Orion 
- for Comtan only: to add 'Magnesium stearate' to 
the list of excipients for the film-coating in the SmPC 
and PL. Tablet core and Film-coating both contain 
magnesium stearate 
- to correct linguistic amendments in Annexes 
- to amend a mistake in the Annex A (only for 
Comtan). 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
WS/0651 
This was an application for a variation following a 
18/12/2014 
n/a 
To include an additional analytical method for the active 
Page 9/11 
 
 
 
 
 
 
 
 
 
 
 
substance carbidopa. 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
To include an additional analytical method for the 
active substance carbidopa. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IAIN/0004 
A.2.a - Administrative change - Change in the 
02/10/2014 
16/10/2015 
SmPC, 
(invented) name of the medicinal product for CAPs 
Labelling and 
PL 
IG/0433/G 
This was an application for a group of variations. 
08/05/2014 
n/a 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0001/G 
This was an application for a group of variations. 
17/03/2014 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
Page 10/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 11/11 
 
 
 
 
 
 
 
